# A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

> **NCT06827457** · PHASE1 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 58 (actual)

## Conditions studied

- Autoimmune Disease

## Interventions

- **DRUG:** GenSci120
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06827457
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-20
- **Primary completion:** 2025-11-27
- **Final completion:** 2025-12-16
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06827457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06827457, "A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06827457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*